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Abstract 
Colorectal cancer is a leading cause of cancer-related mortality worldwide, with Fluorouracil (5-FU)-based chemother-
apy as the major treatment for advanced disease. Many patients with advanced colorectal cancer eventually succumb 
to the disease despite some patients responded initially to chemotherapy. Thus, identifying molecular mechanisms 
responsible for chemotherapy resistance will help design novel strategies to treat colorectal cancer. In this study, we 
established an acquired 5-FU resistant cell line, LoVo-R, from LoVo cells. Through exome sequencing, we discovered 
that elevated GLI1 signaling axis is a major genetic alteration in the 5-FU resistant cells. Hh signaling, a pathway essen-
tial for embryonic development, is an important regulator for residual cancer cells. We demonstrated that knockdown 
of GLI1 or GLI2 sensitized LoVo-R cells to 5-FU treatment, reduced cell invasiveness. The relevance of our studies to 
colorectal cancer patients is reflected by our discovery that high expression of GLI1 signaling molecules was associ-
ated with a high incidence of cancer relapse and a shorter survival in a larger cohort of colorectal cancer patients who 
underwent chemotherapy (containing 5-FU). Taken together, our data demonstrate the critical role of the GLI1 signal-
ing axis for 5-FU resistance in colorectal cancer.
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Background
The overall incidence of CRC has significantly declined in 
the last two decades, largely due to early screening and 
preventative measures in life styles. Currently, colorectal 
cancer (CRC) is still the leading cause of cancer-related 
deaths, with nearly 1.4 million cases a year and ~774,000 
deaths worldwide [1].
Fluorouracil (FU)-based adjuvant chemotherapy has 
been used to treat CRC since 1990s. Adding oxaliplatin 
to FU has resulted in an approximate 20% relative risk 
reduction for disease-free survival. At present, the first 
line treatment of colorectal cancer includes mFOLFOX6 
with or without targeted drugs bevacizumab or cetuxi-
mab [2, 3]. The mFOLFOX6 regimen contains leucovorin 
calcium (folinic acid), fluorouracil, and oxaliplatin. While 
some patients respond initially to chemotherapy, many 
advanced colorectal cancer patients eventually develop 
relapsed disease. Therefore, drug resistance is a major 
barrier to achieve effective gastric cancer treatment.
5-Fu, an analog of uracil with a fluorine atom substi-
tuted at the carbon-5 position of the pyrimidine ring in 
place of hydrogen, fulfills the expectations of biochemi-
cal, pharmacologic, and clinical activity of anticancer 
drugs. The 5-fluorinated pyrimidines have been widely 
used in the treatment of breast, gastric, colorectal, pan-
creatic cancers, and squamous cell carcinomas arising 
in the head and neck [4]. The primary mechanisms of 
action for 5-Fu include (1) incorporation of fluorouridine 
triphosphate into RNA to interfere with RNA synthesis 
and function; (2) inhibition of thymidylate synthase; (3) 
incorporation of fluorodeoxyuridine triphosphate and 
deoxyuridine triphosphate into DNA; and (4) genotoxic 
stress to trigger programmed cell death pathways.
Resistance to 5-FU in CRC is a major clinical prob-
lem. While there are a number of mechanisms reported 
to be responsible for drug resistance [5–9], activation 
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of hedgehog (Hh), wnt and notch signaling pathways is 
quite appealing [10–12]. Like wnt and notch signaling, 
hedgehog signaling is an important regulator for embry-
onic development, tissue polarity, cell differentiation and 
cancer development [5, 9, 13–15]. Thus, specific inhibi-
tors for these signaling pathways may be used to sensitize 
cancer cells to 5-FU treatment. However, the significance 
of Hh (or wnt and notch signaling) for 5-FU resistance in 
colorectal cancer has not been well established.
To elucidate the underlying mechanism for 5-FU resist-
ance in CRC, we established an acquired resistant cell 
line, LoVo-R, through addition of increasing amount of 
5-FU to the LoVo parental cells for 1 year. We compared 
gene expression profiles of LoVo-R cells with that of the 
parental LoVo cells using next generation sequencing. 
We discovered elevated expression of Gli1 as the major 
change in the 5-FU resistant LoVo-R cells. We demon-
strated the significance of Gli transcription factors for 
5-FU resistance. The relevance of our studies in this pair 
of cell lines was reflected in a large cohort of patients 
with colorectal cancer who underwent 5-FU-based 
chemotherapy.
Results
Characteristics of 5‑Fu‑resistant LoVo‑R cell line
LoVo cells were cultured in medium containing step-
wise increased concentrations of 5-Fu for 12  months to 
obtain LoVo-R cell line. There are a number of differ-
ences between the 5-FU resistant LoVo-R cells and the 
parental LoVo cells. Morphologically, we observed sig-
nificant difference between LoVo and LoVo-R cells under 
microscope. Whereas LoVo-R cells have a spindle shape, 
LoVo cells are more epithelial cell-like (Fig. 1a). Second, 
we noticed that LoVo-R cells proliferate much slower 
than the parental cells. The doubling time for LoVo cells 
is ~48 h. In contrast, LoVo-R cells have a doubling time 
of ~96 h. By CCK8 assay, we found that the IC50 for 5-FU 
in LoVo-R cells is 1967.224 μg/ml (15.124 mM) (Fig. 1a). 
On the other hand, the IC50 for 5-FU in the parental 
LoVo cells is 16.6 μg/ml (0.128 mM). The resistant index 
is over 118 (=15.124/0.128), suggesting that LoVo-R is a 
true 5-FU resistant cell line.
Gene expression analysis in LoVo‑R and the parental LoVo 
cells
To understand the molecular basis responsible for drug 
resistance to 5-Fu in LoVo-R cells, we compared gene 
expression profiles between LoVo-R and LoVo cells 
using next generation sequencing. We had three biologi-
cal repeats for each cell type, and we had 150-bp reads 
in both directions for the sequencing (see “Methods” for 
details). Overall, we observed gene expression changes 
in over 10,000 transcripts, with >7000 up-regulated and 
4000 down-regulated in LoVo-R cells (Datasets submit-
ted to GEO datasets, with an ID: 379155). Significant 
changes were listed in Additional file  1: Figures  S1–S5. 
Pathway analyses using the IPA program indicate altera-
tions in several signaling pathways, including growth 
factors (VEGF, MEK), EMT regulation and hedgehog 
signaling (Additional file 1 and Fig. 2a). Hedgehog signal-
ing related regulator GLI1 is known to be vital in cancer 
biology [16, 17]. GLI1 is known to be significantly over-
expressed in colorectal cancer cells [18]. As a major focus 
for our laboratory on Hh signaling, we proposed that 
GLI1 might be a vital factor of 5-Fu resistance in patients 
with colorectal cancer.
To confirm the sequencing data, we performed West-
ern blotting analysis using GLI1 specific antibodies. We 
found that GLI1 protein was higher in LoVo-R cells in 
comparison with the parental LoVo cells (Fig. 1b).
Functional significance of GLI1 for 5‑FU resistance 
in colorectal cancer cells
Considering the functional domains of GLI1, we 
designed three shRNAs to knock down GLI1: shRNA#1, 
shRNA#2 and shRNA#3. Lentiviruses expressing GLI1 
shRNAs were used to infect LoVo-R cells. To test the 
change of LoVo-R cell line in 5-FU resistance after 
knocking down GLI1, we used CCK8 assay to detect 
cell viability in the presence or absence of 5-FU (Fig. 3). 
As expected, Gli1 shRNA expression sensitized LoVo-R 
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Fig. 1 Characterization of 5-FU resistant LoVo-R cells. a Shows 
morphology of LoVo and LoVo-R cells. b Shows the IC50 dose of 5-FU 
calculated from measurement of cell viability in different concentra-
tions of 5-FU (48 h). The X-axis is 5-FU concentration (μg/ml), and the 
Y-axis is O.D. values. Significant difference was indicated by *p < 0.05, 
**p < 0.005, or ***p < 0.0005
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cells to 5-FU treatment, with the IC50 around 280 μg/
ml (2.154 mM), which was much lower to 1967.224 μg/
ml (15.124  mM) in LoVo-R cells. However, the IC50 
was not reduced to the level of the parental LoVo cells, 
which was 16.041  μg/ml (0.123  mM), indicating that 
there are other factors involved in regulation of 5-FU 
resistance.
It is known that GLI2 can regulate Gli1 expression. 
Although the Gli2 expression was not much changed in 
LoVo-R cells, expression of Gli2 was detectable in both 
LoVo and LoVo-R cells. We tested whether Gli2 shRNAs 
affect GLI1 expression and 5-FU resistance in LoVo-R 
cells. We found that the IC50 for 5-FU in Gli2-shRNA-
expressing LoVo-R cells (shown as shGli2) was 0.36 mM 
(the control LoVo-R with an IC50 for 5-FU of 15  mM), 
indicating significantly reduction of IC50 by GLI2 shR-
NAs (p < 0.05) (Fig. 3d). As expected, we found reduced 
expression of both Gli1 and Gli2 in the Gli2 shRNA-
expressing LoVo-R cells (Fig. 4a).
Molecular mechanisms for GLI1‑mediated 5‑FU resistance 
in colorectal cancer cells
To determine the molecular mechanisms underly-
ing Gli1-mediated 5-FU resistance in LoVo-R cells, we 
characterized LoVo-R cells with GLI1-shRNAs or GLI2-
shRNAs for cell morphology, EMT and expression of 
cancer stem cell markers. Although GLI1 and GLI2 
shRNAs resulted in reduction of IC50 for 5-FU, we did 
not observe significant changes in cell morphology (data 
not shown), indicating that GLI1 is not responsible for 
the morphological change in LoVo-R cells. Next, we 
examined EMT markers, and found that GLI1/2 knock-
down reduced expression of vimentin and Snai1 (Fig. 4a, 
b), indicating that EMT regulation is a major mechanism 
by which GLI1 promotes drug resistance in LoVo-R cells. 
In addition, we also assessed expression of cancer stem 
cell markers, and found no significant changes in CD44, 
a commonly used marker for colorectal cancer stem cells 
[19–21] (Fig.  4c). No significant changes were observed 
in Sox2 after GLI1 shRNA expression (Fig.  4c). From 
these, we predict that EMT regulation seems to be the 
major function of GLI1 in LoVo-R cells. While LoVo-R 
cells have more EMT phenotypes (spindle shaped mor-
phology, high vimentin and snai1 expression), knock-
down of GLI1 and GLI2 reduced expression of snai1 
and vimentin. It is known that EMT phenotypes is often 
associated with cell invasiveness [22]. We examined cell 
invasiveness using Boyden chambers, and found that 
GLI2 knockdown significantly reduced cell invasiveness 
(Fig. 5). We found that LoVo-R cells increased the relative 
cell invasiveness by nearly three times, and GLI2 shRNA 
expression reduced the invasiveness back to the basal 
level. We did not see significant changes in cell invasive-
ness after expression of control shRNAs (Fig.  5). These 
Fig. 2 Up-regulated of GLI1 signaling axis in LoVo-R (in comparison with LoVo) cells. After next generation sequencing, we performed ingenu-
ity pathway analysis (IPA). a Shows up-regulation of GLI1 and its signaling molecules, and the up-regulated genes are in red. b Detection of GLI1 
protein in LoVo and LoVo-R cells. β-actin was used as the internal control
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Fig. 3 The effect of GLI1/2 knockdown on 5-FU response in LoVo-R cells. a Real-time PCR detection of GLI1 after GLI1 shRNA expression. b Detection 
of GLI1 protein by Western blotting. c The effect of GLI1-ShRNAs (shown as shGLI1) on the IC50 of 5-FU (measured as shown in Fig. 1b). d Effects of 
GLI2 shRNAs (shown as shGLI2) on 5-FU response. Significant difference was indicated by *p < 0.05, **p < 0.005, or ***p < 0.0005
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Fig. 4 The effects of GLI1 knockdown on gene/protein expression. a Real-time analysis of GLI1, GLI2, Snai1 and Snai2 in GLI2 shRNAs-expressing 
LoVo-R cells. Significant difference was indicated by ***p < 0.0005. b Effects of Gli2 shRNAs on vimentin expression. c The effect of GLI1 knockdown 
on Sox2 and CD44 proteins
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data indicate that expression of Gli1 is critical for 5-FU 
resistance and for cell invasiveness in LoVo-R cells.
Relevance of the Gli1 signaling axis in human colorectal 
cancer
The relevance of our data to human colorectal cancer 
patients was reflected by analysis of cancer relapse in 
a large cohort of patients with colorectal cancer from 
the TCGA data sets (The results here are in whole or 
part based upon data generated by the TCGA Research 
Network:  http://cancergenome.nih.gov/; http://www.
cbioportal.org) [23, 24]. All patients underwent chemo-
therapy (all had 5-FU), which is the standard care for 
colorectal cancer patients. We correlated the high or 
low expression of GLI1/GLI3/pathway molecules in the 
tumor with cancer relapse (Additional file 2). We found 
that tumor recurrence occurred in 33% of the patients 
with tumors expressing high levels of GLI1 and the sign-
aling molecules. In contrast, those patients with low 
GLI1/GLI3 expression had only 19.5% of patients with 
relapse. The odd ratio for cancer relapse in high GLI1/
GLI3 expression is 1.69, indicating that high expression 
of GLI1/GLI3 signaling molecules increases the risk of 
cancer relapse by 69% in colorectal cancer patients after 
chemotherapy. In consistent with cancer relapse, we also 
found that patients with high expression of GLI1/GLI3 
and associated molecules in the primary tumors had 
worse patient survival (Fig.  6). Since all patients under-
went chemotherapy (containing 5-FU), this correlation 
further support our hypothesis that high expression of 
GLI1/GLI3 molecules in the tumor indicates poor out-
comes from 5-FU associated chemotherapy treatment.
Taken all the data together, our study reveals a new 
mechanism for 5-FU resistance in colorectal cancer. We 
found activation of the GLI1 signaling axis in acquired 
resistant cancer cells to 5-FU treatment. Down-regu-
lation of GLI1 or GLI2 sensitized cancer cells to 5-FU 
treatment. We believe that Gli1 mediates its resistance 
to 5-FU through direct regulation of EMT and cell inva-
siveness. The relevance of our data to colorectal can-
cer patients is reflected by the increasing risk of cancer 
relapse and poor treatment outcomes in patients with 
high GLI1 expression in the primary tumor.
Discussion
Our study has revealed a novel mechanism responsible 
for 5-FU based chemotherapy resistance and its link to 
cancer relapse. As a major contributor for cancer-related 
mortality, many colorectal cancer patients are diagnosed 
with advanced disease where the five-year survival rate is 
still low (12%) [25]. Chemotherapy with 5-FU has been 
the first line treatment option for advanced colorectal 
cancer, but many patients develop cancer relapse after 
initial treatment. Although the regulatory mechanisms 
for chemotherapy resistance in colorectal cancer have 
been reported, few studies have been linked the mecha-
nisms to cancer relapse [18, 26–36]. Our results indicate 
that elevated expression of GLI1 and the signaling mole-
cules are an important mechanism for 5-FU resistance in 
colorectal cancer cells. We have data to show that knock-
ing down GLI1 or GLI2 will sensitize cancer cells to 5-FU 
treatment. More importantly, we have shown that high 
expression of GLI1 and its signaling molecules is associ-
ated with an increasing risk of developing cancer relapse 
and a poor survival in colorectal cancer patients who 
underwent 5-FU based chemotherapy, indicating that 
our studies is relevant to the colorectal cancer patients. 
While the additional understanding of GLI1-mediated 
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Fig. 5 Cell invasiveness assay. Different cells were subjected to cell invasiveness as described in the methods, and invasive cells were visualized by 
blue in the staining (a). b Shows the summary from three independent experiments, with the value (number of invasive cells) from LoVo cells as 100
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5-FU resistance is still needed, we have shown that reg-
ulation of EMT is a major mechanism. Since inhibitors 
for GLI1 are already available, we predict that these novel 
reagents, together with chemotherapy, will improve the 
overall survival of gastric cancer patients.
It is unlikely that any one mechanism will be respon-
sible for all the resistance. There are many reports on 
the molecular mechanisms responsible for resistance to 
cytotoxic chemotherapy or targeted therapy, particu-
larly for the acquired resistance. In our studies, we also 
noticed many changes in the acquired resistant LoVo-R 
cells, including morphological change, cell prolifera-
tion change and gene expression changes (Figs. 1 and 2). 
While knockdown of GLI1 and GLI2 sensitized cancer 
cells to 5-FU, the IC50 was still higher than the parental 
cells. Thus, we believe that there are other mechanisms 
responsible for 5-FU resistance in LoVo-R cells, which 
will need further investigation.
Identifying GLI1 as a factor driving 5-FU resistance 
has significant clinical implications. First, our studies 
explained why SMO antagonists did not work in colo-
rectal cancer treatment in previous clinical trials [37, 
38]. We found that Shh expression was not significantly 
altered by 5-FU in LoVo-R cells. We further demon-
strated and SMO antagonist BMS833923 was not able 
to sensitize cancer cells to 5-FU (data not shown here), 
suggesting that up-regulation of GLI1 was not caused 
by canonical Hh signaling. This implies that the SMO 
antagonists, such as vismodegib [39], will not be effective 
in sensitizing colorectal cancer cells to chemotherapy, 
which was shown in the previous clinical trial. Second, 
our data indicate that specific inhibitors to GLI molecules 
may be more effective in sensitizing cancer cells to 5-FU 
based chemotherapy. Currently, there are several small 
molecules now available to target GLI1, such as GANT61 
and arsenic trioxide [40–43].
Conclusions
We report a novel mechanism by which colorectal can-
cer cells gain acquired fluorouracil (5-FU) resistance. We 
found that elevated GLI1 signaling axis is responsible for 
5-FU resistance both in cultured cell lines and in relevant 
cancer patients. It is thus predicted that agents inhibiting 
GLI1 activity may be effective in sensitizing colorectal 
cancer cells to 5-FU-based chemotherapy.
Methods
LoVo cell line and cell culture
The human colorectal cancer cell line LoVo was pur-
chased from ATCC. Cells were cultured in 90% RPMI 
Cases with high GLI1 signaling axis
Cases with low GLI1 signaling axis
Fig. 6 Kaplan–Meier Survival analysis comparing patients with high GLI1 signaling axis in the tumor with those patients with low GII1 signaling. The 
results here are in whole or part based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov/
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1640 medium (Gibco, 11875085) with 10% fetal bovine 
serum (FBS) (Gibco, 1009-141), 50 U/ml Penicillin and 
50 μg/ml Streptomycin liquid (Gibco, 15070063) at 37 °C 
under 5%  CO2 atmosphere (Thermo, HERAcell 240).
Reagents and antibodies
5-fluorouracil reagent was purchased from Sigma 
(F6627). Powder was dissolved in dimethyl sulfoxide and 
sub-packed in 1.5  ml EP tubes, then stocked at −80  °C 
until use. Western blot antibodies against Gli1 (Cell sign-
aling), CD44 (ABCam), E-Cadherin (ABCam), Snail (Cell 
Signaling) and Vimentin (Cell Signaling) were purchased 
from ABCam Inc. or Cell Signaling Technology Inc. The 
HRP-conjugated secondary antibodies were purchased 
from Santa Cruz Biotechnology.
Establishment of 5‑Fu‑resistant LoVo‑R cell line
5-Fu resistance colorectal cancer cell line LoVo-R was 
generated from parent LoVo cell line by exposed to gra-
dient concentrations of 5-Fu. Briefly, LoVo cells were 
cultured in fresh medium without drugs for 24  h. Sub-
sequently, medium was changed by adding 10  μM 5-Fu 
in complete medium. LoVo cells was exposed to 5-Fu for 
48  h, then culture cells in fresh medium without 5-Fu 
for about a week. When cells reached 70% confluence, 
repeated above steps for several times until they were sta-
ble in 1×  IC50. After that, cells were subjected into 2×, 
3×…IC50. After 12 months’ selection, the 5-Fu-resistant 
cell line LoVo-R was used for this study.
Determination of 50% cell growth inhibition  (IC50) by CCK8 
assay
Cells were adjusted to 5  ×  104/ml using complete 
medium, and inoculated to a 96-wells plate, with 100 
μL cell suspension for each well. Five to eight wells were 
prepared for each sample. After cultured for 24 h, three 
treatment groups were used: group A with no cells for the 
background; group B without 5-Fu to calculate the basic 
metabolism; and group C with different concentrations 
of 5-Fu. Subsequently, 10  μg/ml CCK8 was added into 
each well for 1 h. Absorbance was detected by Microplate 
Reader (Thermo Scientific). A similar assay was also per-
formed using Alarma blue assay [44].
Cell migration assay
Migration of cells was performed using QCM™24-Well 
Colorimetric Migration Assay Kit (Millipore) accord-
ing to the manufacturer’s instructions. Cells (1  ×  105) 
in 300  µl serum-free medium were added to the upper 
chambers and cultured for 48  h and 72  h. Non-migrat-
ing or non-invading cells were removed with cottons 
swabs, cells that migrated to the bottom of the mem-
brane were stained, and counted under microscope and 
photographed. Three independent experiments were per-
formed for each sample.
Lentivirus vector construction and transfection
Based on Transcriptome Sequencing Database data, we 
designed three knock-down sites—shRNA#1, shRNA#2 
and shRNA#3 for GLI1. The target sequences were as 
follows:
shRNA#1 (5′-CCGGTACATCAACTCCGGC-
CAATAGCTCGAGCTATTGGCCGGAGTTGATG-
TATTTTT); shRNA#2 (5′-CCGGCCTGATTATCTT
CCTTCAGAACTCGAGTTCTGAAGGAAGATAAT
CAGGTTTTT);shRNA#3 (5′-CCGGGCTCAGCTT-
GTGTGTAATTATCTCGAGATAATTACACACAA-
GCTGAGCTTTTT). We purchased constructed GLI2 
shRNAs and the control shRNAs from Sigma. Expression 
of shRNAs was donw with lentivirus-mediated infection. 
Stable clones were selected by continuous treatment with 
Puromycin (1.0 mg/ml; Gibco, New York, USA).
Western blot analyses
Cells from 10  cm dishes were lysed in lysis buffer (1% 
NP-40) on ice for 30  min. Proteins were separated by 
SDS-PAGE, and then transferred to a onto a nitrocel-
lulose membrane. Then the membrane was incubated 
in the first antibody followed by the secondary anti-
body. Protein bands were detected by using an enhanced 
chemiluminescence detection system. β-actin was used 
as the internal control.
RNA preparation and real‑time PCR
RNA was extracted from cells using TRIzol Reagent (Inv-
itrogen) and 1 μg cDNA was synthesized from extracted 
total RNA using the PrimeScript™ RT-PCR Kit (Takara) 
according to the manufacture’s instruction. Quantitative 
PCR was carried out with the  PrimeScript® RT reagent 
Kit (Takara) on an ABI Prism 7900HT (Applied Biosys-
tems, Foster City).
Transcriptomic analysis using RNAseq
For transcriptomic analysis, total mRNA of LoVo and 
LoVo-R cells were extracted using TRIzol Reagent (Invit-
rogen). Equal amount of mRNA should be assured, then 
RNAs were used to construct the library. Sequencing was 
conducted using Illumina HiSeq-2000. Analyzing process 
was conducted as the normal bioinformatics analyzing 
method. The RNA abundance was evaluated by Reads 
per kilobases per million reads (RPKM).
Statistical analyses
Analyses were performed using GraphPad Prism soft-
ware for windows version 6 (Graphpad software, 
San Diego, CA). Student’s t tests were performed for 
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statistical analysis with two groups. P value was calcu-
lated using unpaired ANOVA. Significance was discrimi-
nated as *p < 0.05, **p < 0.01, ***p < 0.001. A two-tailed 
value of p less than 0.05 was considered to be statistically 
significant. Odd ratio was calculated according to a pre-
viously described formula [45].
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